PT  - JOURNAL ARTICLE
AU  - Scott L. Sugar
AU  - Larry R. Hutson, Jr.
AU  - Patrick Shannon
AU  - Leslie C. Thomas
AU  - Bobby D. Nossaman
TI  - Comparison of Extended-Release Epidural Morphine With Femoral Nerve Block to Patient-Controlled Epidural Analgesia for Postoperative Pain Control of Total Knee Arthroplasty: A Case-Controlled Study
DP  - 2011 Mar 20
TA  - Ochsner Journal
PG  - 17--21
VI  - 11
IP  - 1
4099  - http://www.ochsnerjournal.org/content/11/1/17.short
4100  - http://www.ochsnerjournal.org/content/11/1/17.full
SO  - Ochsner J2011 Mar 20; 11
AB  - Background: Because newer anticoagulation strategies for total knee replacement present potentially increased risk of neuraxial analgesia, there is movement away from using patient-controlled epidural analgesia (PCEA) for pain control. This concern opens the door for other regional modalities in postoperative analgesia, including the use of extended-release epidural morphine (EREM) combined with a femoral nerve block (FNB).Methods: This study was a prospective observational chart review with the use of recent historical controls in patients undergoing unilateral total knee replacement. Outcomes of interest were 0-, 24-, and 48-hour postoperative pain scores using the visual analog scale (VAS); incidence of side effects; and time spent in the postanesthesia care unit (PACU).Results: Postoperative pain scores at 24 and 48 hours in the EREM and FNB group (n  =  14; 2.6 ± 0.6 and 5.0 ± 0.9, respectively) were comparable to the PCEA group (n  =  14; 3.8 ± 0.6 and 4.2 ± 0.9). The PACU time was shorter in the EREM and FNB group (2.4 ± 0.3 hours) compared with PCEA (3.6 ± 0.3 hours, P  =  .02). No statistically significant difference was found in the incidence of side effects between the 2 groups.Conclusions: The VAS scores at 24 and 48 hours indicate that EREM and FNB provide comparable analgesia to PCEA. The trend toward shorter PACU times represents an opportunity for cost-identification analysis. The study data are limited by their observational nature and the small number of patients involved; nevertheless, this study demonstrates a therapeutic equivalence to PCEA that may be more cost effective.